Latest news with #ALT
Time of India
7 days ago
- Health
- Time of India
3 vegetables a gastroenterologist eats to protect the liver
Gastroenterologist Dr. Joseph Salhab highlights the importance of diet for liver health and recommends incorporating specific vegetables. Broccoli, rich in sulforaphanes, aids detoxification, while beetroot, containing betalains, reduces oxidative stress and lowers liver enzymes. Artichokes, packed with cyanurin, act as a powerful antioxidant, promoting liver cell regeneration and improved bile production. The largest organ in the human body, the liver performs over 500 functions, including the digestion of proteins, mineral storage, bile production, and blood filtration. Despite its significance, liver diseases are on the rise across the globe. Lifestyle factors, including diet, play a crucial role in liver health. Dr. Joseph Salhab, a Florida-based gastroenterologist, has shared about three vegetables he incorporates into his diet to boost liver function. Let's take a look. Broccoli The first vegetable on Dr. Salhab's list is broccoli. Cruciferous vegetables, including broccoli, are known for their liver-protective effects. Broccoli is rich in sulforaphanes, naturally occurring compounds linked to improving the liver's detoxification processes. A 2015 study has shown that broccoli sprout extract significantly reduced ALT and gamma-glutamyl transpeptidase (γ-GTP) levels in men with fatty liver disease, which improved liver function. For those who do not enjoy broccoli, the doctor suggested, 'If you don't like broccoli, you could probably get the same benefit from some of the other cruciferous vegetables, like cabbage, kale, or Brussels sprouts.' Beetroot Beetroot is another vegetable that the gastroenterologist incorporates into his diet. 'Beets contain something called betalains. And betalains are what give it its reddish-purplish color. Betalains reduce oxidative stress within the liver. And it allows it to heal,' the doctor said, in a video shared on Instagram. Beetroot is a great option for those struggling with liver diseases, including fatty liver. A 2023 meta-analysis found that beetroot juice supplementation significantly lowered liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are key markers of liver stress, in patients with NAFLD. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Beyond Text Generation: An AI Tool That Helps You Write Better Grammarly Install Now Undo This vegetable can also improve serious liver conditions such as hepatic steatosis, where excess fat is stored in the liver. Beets are also rich in folate and manganese, which improve the metabolic processes in the liver. You can either roast, juice, or grate beets into salads to improve liver health. Artichokes Artichokes are also rich in antioxidants and are said to be rich in polyphenols, quercetin, and rutin, which protect cells from oxidative damage. They also contain vitamin C, luteolin, and silymarin, which have powerful antioxidants that fight inflammation. Yes, this might come as a surprise to you. But who knew something as delectable as artichokes could improve liver function! Dr. Salhab has described artichokes as 'one of the best liver health foods' due to their high levels of antioxidants. 'We have some good evidence that artichokes are one of the best liver health foods. And that's because they include something called cyanurin, which is a powerful antioxidant for the liver,' the doctor said. This antioxidant helps the liver cells to regenerate and also improve bile production, which helps in the breakdown of fats and the removal of toxins. 'I like to make it as a spread and put it on some sourdough bread. And it's a perfect lunch,' he adds. Supreme Court Pushes Central Govt to Finalise FOPL: What It Means & Why It Matters? | Explained
Economic Times
12-07-2025
- Business
- Economic Times
Cryptocurrency Live News & Updates : Stellar's XLM Price Soars Significantly
13 Jul 2025 | 01:05:13 AM IST Stellar Lumens (XLM) surged over 72% this week, reaching $0.4045, driven by increased futures open interest and a rise in stablecoin supply within its ecosystem. Stellar Lumens (XLM) has experienced a remarkable price surge, climbing to $0.4045, marking its highest level since February. This increase follows a significant rise in futures open interest, which reached $345 million, indicating heightened liquidity and demand. Additionally, the stablecoin supply on the Stellar network hit a record high of $627 million, although this figure includes a substantial asset from the Franklin Onchain US Government Money Fund. Meanwhile, the number of active addresses and transactions on the Stellar network also saw notable increases. In contrast, the broader crypto market is witnessing smaller altcoins like Kyber Network Crystal (KNC) making headlines with a staggering 95.3% surge, following the launch of its crosschain platform. Other altcoins, such as Kori and ALT, are also experiencing significant gains, driven by social media hype and speculative trading. As XRP stabilizes around $2.70, traders are advised to approach these volatile altcoins with caution, as the market dynamics shift and new developments unfold. Show more
Business Insider
28-06-2025
- Business
- Business Insider
Jefferies says market reaction to IMPACT data is overkill
Jefferies believes Altimmune (ALT) stock dropping 50% after the company announced results from its IMPACT study is overkill, as data met the firm's most likely scenario. Jefferies sees pemvidutide as a viable/safe drug uniquely positioned in MASH as the first incretin to hit statistical significance on histology at 24 weeks with potential to deepen with time and thinks these factors differentiate the drug from the fibroblast growth factor 21 class, the firm told investors in a research note. Jefferies added that the company can take meaningful share in the growing MASH market if successful. The firm reiterated a Buy rating and $28 price target on shares. Confident Investing Starts Here:
Economic Times
26-06-2025
- Business
- Economic Times
Altimmune's stock plummets over 60% as liver drug falls short in trial
Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key MASH trial. While it helped with MASH resolution and weight loss, the lack of clear fibrosis improvement spooked investors. Shares crashed over 60%, sending shockwaves through the biotech market. Investors are now waiting for FDA feedback and the next steps for pemvidutide. With MASH being a major health issue and no approved treatment yet, all eyes are on how Altimmune moves forward. This could still be a game-changer—or a missed opportunity. Altimmune stock plummeted after disappointing MASH trial results, causing panic among investors. Despite hitting MASH resolution goals, the lack of fibrosis improvement pushed shares down 60%. Here's what went wrong—and what's next for pemvidutide and Altimmune's future. Tired of too many ads? Remove Ads What is the current stock price of Altimmune? Current price: $7.71 $7.71 52-week high: $11.16 $11.16 52-week low: $3.55 $3.55 Market cap: Estimated between $558 million to $625 million Did pemvidutide meet its primary endpoint? Tired of too many ads? Remove Ads 59.1% of patients on the 1.2 mg dose saw MASH resolution of patients on the 1.2 mg dose saw MASH resolution 52.1% achieved resolution on the 1.8 mg dose achieved resolution on the 1.8 mg dose Only 19.1% on placebo met this benchmark What about weight loss and secondary benefits? 5.0% weight loss at 1.2 mg at 1.2 mg 6.2% at 1.8 mg, compared to 1.0% in placebo Why did the stock crash despite positive results? Are analysts still bullish on Altimmune? What are the short-term stock trends for ALT? Tired of too many ads? Remove Ads What is MASH treatment? What's next for Altimmune and pemvidutide? FAQs: Altimmune's stock (NASDAQ: ALT) plunged roughlyin pre-market trading today after it announced mixed results from its mid-stage (IMPACT Phase 2b) trial evaluating its liver drug,, for metabolic dysfunction-associated steatohepatitis (MASH).The drug showed promising results in reducing liver fat and achieving MASH resolution, but failed to deliver strong statistical evidence for fibrosis improvement—a key benchmark in this disease of, Altimmune is trading at. This price represents a significant pullback from its recent highs, though it remains above its 52-week The trial hit its primary goal: resolution of MASH without worsening liver fibrosis. At 24 weeks:These results were statistically significant and well above expectations, positioning pemvidutide as a serious contender in the MASH also highlighted significant weight loss among trial participants:This positions pemvidutide alongside other GLP-1 class weight-loss drugs, a category currently generating high investor and consumer issue lies with the fibrosis endpoint. While there were improvements, the trial didn't reach statistical significance in its primary analysis of fibrosis reduction—a major goal in MASH treatment. Though an AI-assisted analysis showed 30.6% of patients had ≥60% reduction in fibrosis (vs. 8.2% placebo), it wasn't enough to reassure investors looking for definitive progress in this despite the sell-off, Wall Street remains optimistic about Altimmune's long-term prospects. The stock currently holds afrom suggests potential upside of nearlyfrom the current price level, assuming pemvidutide regains investor confidence in later ALT has been highly volatile and is currently trading in the. Short-term charts show, with some analysts recommending caution until the stock finds support or short for Metabolic dysfunction-associated steatohepatitis, is the new name for what was previously called NASH (Non-Alcoholic Steatohepatitis). It's a serious form of fatty liver disease that occurs when fat builds up in the liver and causes inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver will hold an investor webcast to discuss results and plans to meet the FDA for an End-of-Phase 2 meeting by late 2025. A Phase 3 trial is still under stock crashed after its MASH drug failed to show strong results in improving liver the company plans to meet the FDA and may start a Phase 3 trial.
Time of India
26-06-2025
- Business
- Time of India
Altimmune's stock plummets over 60% as liver drug falls short in trial
Altimmune's stock (NASDAQ: ALT) plunged roughly 60–64% in pre-market trading today after it announced mixed results from its mid-stage (IMPACT Phase 2b) trial evaluating its liver drug, pemvidutide , for metabolic dysfunction-associated steatohepatitis (MASH). The drug showed promising results in reducing liver fat and achieving MASH resolution, but failed to deliver strong statistical evidence for fibrosis improvement—a key benchmark in this disease area. What is the current stock price of Altimmune? As of June 26, 2025 , Altimmune is trading at $7.71 per share . This price represents a significant pullback from its recent highs, though it remains above its 52-week low. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo Current price: $7.71 52-week high: $11.16 52-week low: $3.55 Market cap: Estimated between $558 million to $625 million Also Read: US stock futures rise: Dow, S&P 500, and Nasdaq edge higher as Nvidia, BlackBerry, and QuantumScape rally Did pemvidutide meet its primary endpoint? Yes. The trial hit its primary goal: resolution of MASH without worsening liver fibrosis. At 24 weeks: Live Events 59.1% of patients on the 1.2 mg dose saw MASH resolution 52.1% achieved resolution on the 1.8 mg dose Only 19.1% on placebo met this benchmark These results were statistically significant and well above expectations, positioning pemvidutide as a serious contender in the MASH space. Also Read: Intel layoffs 2025: Design engineers, software architects lose jobs - these key divisions are next What about weight loss and secondary benefits? Altimmune also highlighted significant weight loss among trial participants: 5.0% weight loss at 1.2 mg 6.2% at 1.8 mg , compared to 1.0% in placebo This positions pemvidutide alongside other GLP-1 class weight-loss drugs, a category currently generating high investor and consumer interest. Why did the stock crash despite positive results? The issue lies with the fibrosis endpoint. While there were improvements, the trial didn't reach statistical significance in its primary analysis of fibrosis reduction—a major goal in MASH treatment. Though an AI-assisted analysis showed 30.6% of patients had ≥60% reduction in fibrosis (vs. 8.2% placebo), it wasn't enough to reassure investors looking for definitive progress in this area. Are analysts still bullish on Altimmune? Yes, despite the sell-off, Wall Street remains optimistic about Altimmune's long-term prospects. The stock currently holds a "Strong Buy" rating from analysts. That suggests potential upside of nearly 190% from the current price level, assuming pemvidutide regains investor confidence in later trials. What are the short-term stock trends for ALT? Technically, ALT has been highly volatile and is currently trading in the mid-range of its 52-week band . Short-term charts show neutral-to-bearish signals , with some analysts recommending caution until the stock finds support or stabilizes. What is MASH treatment? MASH, short for Metabolic dysfunction-associated steatohepatitis, is the new name for what was previously called NASH (Non-Alcoholic Steatohepatitis). It's a serious form of fatty liver disease that occurs when fat builds up in the liver and causes inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver cancer. What's next for Altimmune and pemvidutide? Altimmune will hold an investor webcast to discuss results and plans to meet the FDA for an End-of-Phase 2 meeting by late 2025. A Phase 3 trial is still under consideration. FAQs: What caused Altimmune stock to crash after the MASH trial? The stock crashed after its MASH drug failed to show strong results in improving liver fibrosis. Is Altimmune still moving forward with pemvidutide? Yes, the company plans to meet the FDA and may start a Phase 3 trial.
